Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Inclusion Criteria (for CHF): 1. Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, or pulmonary congestion. 2. Non-hypovolemic and Non-acute hyponatremia with a serum sodium \< 135mEq/L before randomization. 3. Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period. 4. Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration. 5. Age:18～80 (when informed consent is obtained)，male or female. 6. In-patient subjects. 7. Informed consent. Inclusion Criteria (for hepatic cirrhosis): 1. Patients with hepatic edema. 2. Non-hypovolemic and non acute hyponatremia with a serum sodium \< 135mEq/L before randomization. 3. Age:18～65 (when informed consent is obtained)，male or female. 4. In-patient subjects. 5. Informed consent. Inclusion Criteria (for SIADH and others): 1. Patients with SIADH arising from a variety of etiologies. 2. Non-hypovolemic and non acute hyponatremia with a serum sodium \< 135mEq/L before randomization. 3. Age:18～80 (when informed consent is obtained)，male or female. 4. In-patient subjects. 5. Informed consent.